FUNDAMENTAL AND CLINICAL STUDIES ON HBK IN UROLOGICAL FILED
スポンサーリンク
概要
- 論文の詳細を見る
HBK was developed as a useful antibiotic for bacteria resistant to other aminoglycoside antibiotics.<BR>Fundamental study: From results of absorption and excretion (100 mg intramuscular administration) in healthy volunteers, the average-of penk serum level of HBK was 9.00μg/ml (15 min. after injection), AMK was 6.71μg/ml (30 min. after injection) and T1/2s were 2.09 and 1.44 hr. respectively. Fifty per-cent and over of HBK and AMK were excreted in urine within the first 4 hours, and the urinary recovery rates within the first 24 hours were 74.6, 84.3% respectively.<BR>Clinical study: 18 patients with complicated urinary tract, infections and 3 patients with other infections were treated with intramuscular administration or 1 hour drip-infusion of HBK at the dose of 100-200 mg for 5-7 days. The clinical results of 12 cases were assessed by; UTI Drug Efficacy Evaluation Criteria. The results were rated as excellent in 1 case, good in 3 cases and poor in 8 cases with an efficacy rate of 33%. Bacteriologically, 11 out of 19 (58;sv) strains were eradicated. Six out of 12 mixed infections were rated as good in only 1 case and poor in other 5 cases, so the efficacy rate became lower. As to the case with acute prostatitis, acute uncomplicated pyelonephritis and acute epididymitis, the Doctor's evaluation was "excellent" in all 3 cases.<BR>No side effect was observed in these 21 cases and abnormal laboratory findings such as a slight elevations of S-GOT and S-GPT, S-GOT, S-GPT and Al-P in one case each were observed after treatment.<BR>From these results it is suggested that is a safe AGs and useful for moderate infections of the field of urology.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.